S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Bausch + Lomb Stock Price, News & Analysis (NYSE:BLCO)

$15.64
+0.30 (+1.96%)
(As of 12/8/2023 ET)
Compare
Today's Range
$15.21
$15.69
50-Day Range
$14.87
$17.57
52-Week Range
$14.37
$21.95
Volume
1.19 million shs
Average Volume
425,743 shs
Market Capitalization
$5.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.10

Bausch + Lomb MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
28.5% Upside
$20.10 Price Target
Short Interest
Bearish
9.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Bausch + Lomb in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-1.54%
From $0.65 to $0.64 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.42 out of 5 stars

Medical Sector

887th out of 954 stocks

Medical Instruments & Supplies Industry

10th out of 10 stocks


BLCO stock logo

About Bausch + Lomb Stock (NYSE:BLCO)

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Stock Price History

BLCO Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Bausch & Lomb Corp BLCO
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
6 Analysts Have This to Say About Bausch & Lomb
See More Headlines
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Ophthalmic goods
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
12,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.10
High Stock Price Target
$25.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+28.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$6 million
Pretax Margin
-2.80%

Debt

Sales & Book Value

Annual Sales
$3.97 billion
Cash Flow
$2.20 per share
Book Value
$20.29 per share

Miscellaneous

Free Float
N/A
Market Cap
$5.49 billion
Optionable
Not Optionable
Beta
0.20
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Osama A. Eldessouky (Age 51)
    Executive VP & CFO
    Comp: $1.09M
  • Dr. Yehia Hashad M.D. (Age 56)
    Executive VP of Research & Development and Chief Medical officer
    Comp: $1.09M
  • Mr. Brenton L. Saunders J.D. (Age 53)
    CEO & Chairman
  • Mr. Alan Waterhouse CPFA (Age 63)
    MBA, Executive VP and Chief Supply Chain & Operations Officer
  • Mr. Frederick J. Munsch (Age 53)
    Senior VP, Controller & Chief Accounting Officer
  • Mr. A. Robert D. Bailey (Age 60)
    Executive VP & Chief Legal Officer
  • Mr. Jonathon L. Kellerman
    Chief Compliance Officer
  • T.J. Crawford
    Chief Communications Officer
  • Dr. Manisha A. Narasimhan Ph.D. (Age 46)
    Chief Corporate Development & Digital Officer
  • Ms. Asli Gevgilili
    Executive VP & Chief Human Resources Officer














BLCO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch + Lomb stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BLCO shares.
View BLCO analyst ratings
or view top-rated stocks.

What is Bausch + Lomb's stock price target for 2024?

8 analysts have issued 1 year target prices for Bausch + Lomb's shares. Their BLCO share price targets range from $16.00 to $25.00. On average, they predict the company's stock price to reach $20.10 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for BLCO
or view top-rated stocks among Wall Street analysts.

How have BLCO shares performed in 2023?

Bausch + Lomb's stock was trading at $15.51 on January 1st, 2023. Since then, BLCO shares have increased by 0.8% and is now trading at $15.64.
View the best growth stocks for 2023 here
.

Are investors shorting Bausch + Lomb?

Bausch + Lomb saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,840,000 shares, an increase of 10.0% from the October 31st total of 3,490,000 shares. Based on an average trading volume of 385,900 shares, the days-to-cover ratio is presently 10.0 days. Currently, 10.0% of the company's stock are sold short.
View Bausch + Lomb's Short Interest
.

When is Bausch + Lomb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our BLCO earnings forecast
.

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) issued its quarterly earnings data on Wednesday, November, 1st. The company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $990.68 million. Bausch + Lomb had a negative net margin of 5.22% and a positive trailing twelve-month return on equity of 3.63%. The business's revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.31 earnings per share.

What ETFs hold Bausch + Lomb's stock?

ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT).First Trust US Equity Opportunities ETF (FPX).

When did Bausch + Lomb IPO?

(BLCO) raised $788 million in an IPO on Friday, May 6th 2022. The company issued 35,000,000 shares at a price of $21.00-$24.00 per share.

Who are Bausch + Lomb's major shareholders?

Bausch + Lomb's stock is owned by a number of institutional and retail investors. Top institutional investors include Eminence Capital LP (1.71%), Goldentree Asset Management LP (1.44%), Maple Rock Capital Partners Inc. (0.92%), River Road Asset Management LLC (0.45%), Alberta Investment Management Corp (0.39%) and Laurion Capital Management LP (0.29%).

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:BLCO) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -